Azitra, Inc. (NYSEAMERICAN:AZTR) Shares Shorted: Short Interest Down 65.7% in September

Azitra, Inc. (NYSEAMERICAN:AZTR – Get Free Report) was the target of a large decrease in short interest in the month of September. As of September 30th, there was short interest totaling 240,809 shares, a decrease of 65.7% from the September 15th total of 701,345 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average daily trading volume, of 889,711 shares, the short-interest ratio is presently 0.3 days.

Azitra Stock Performance

NYSEAMERICAN:AZTR traded down $0.01 during midday trading on Monday, reaching $0.12. The stock had a trading volume of 257,747 shares, compared to its average volume of 8,211,656. The firm’s fifty day simple moving average is $0.15 and its 200-day simple moving average is $0.18. Azitra has a 1-year low of $0.10 and a 1-year high of $1.09.

Azitra (NYSEAMERICAN:AZTR – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.05). On average, sell-side analysts anticipate that Azitra will post -0.20 EPS for the current year.

About Azitra

(Get Free Report)

Azitra, Inc is a clinical-stage biotechnology company focused on developing live biotherapeutic products for dermatological conditions. The company uses microbiome science and genetic engineering to develop beneficial bacteria designed for topical application to the skin.

Azitra’s research programs have focused on conditions including atopic dermatitis, acne vulgaris and other skin disorders associated with impaired barrier function or microbial imbalance. Its pipeline has included engineered strains of skin-associated bacteria intended to deliver therapeutic proteins or other biological effects directly to affected areas.

The company was founded in 2014 and is based in New Haven, Connecticut.

Recommended Stories

Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.